174 related articles for article (PubMed ID: 27919309)
1. COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA.
Castro Jaramillo HE; Moreno Viscaya M; Mejia AE
Int J Technol Assess Health Care; 2016 Jan; 32(5):337-347. PubMed ID: 27919309
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy.
Coppola A; D'Ausilio A; Aiello A; Amoresano S; Toumi M; Mathew P; Tagliaferri A;
Haemophilia; 2017 May; 23(3):422-429. PubMed ID: 28181369
[TBL] [Abstract][Full Text] [Related]
5. Immediate versus delayed breast reconstruction in breast cancer patients in Colombia: A costutility analysis.
Perea AH; Rosselli D
Biomedica; 2018 Sep; 38(3):363-378. PubMed ID: 30335242
[TBL] [Abstract][Full Text] [Related]
6. Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A.
Miners A
Haemophilia; 2009 Jul; 15(4):881-7. PubMed ID: 19473422
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Hemophilia B Without Inhibitors in China.
Liu G; Xin Q; Chen Z; Li L; Chen T; Wu R
Clin Ther; 2021 Sep; 43(9):1536-1546. PubMed ID: 34392959
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A.
Lotfi F; Talebianpour H; Keshavarz K; Emadi F; Bordbar MR; Bastani P
Daru; 2020 Jun; 28(1):287-293. PubMed ID: 32323144
[TBL] [Abstract][Full Text] [Related]
9. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
[No Abstract] [Full Text] [Related]
10. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.
Mejía A; Senior JM; Ceballos M; Atehortúa S; Toro JM; Saldarriaga C; Mejía ME; Ramírez C
Biomedica; 2015; 35(4):531-40. PubMed ID: 26844442
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran.
Zahedi Z; Karimi M; Keshavarz K; Haghpanah S; Ravangard R
Hematology; 2021 Dec; 26(1):240-248. PubMed ID: 33594948
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China.
Gu C; Huang H; Han Y
Adv Ther; 2022 Aug; 39(8):3777-3788. PubMed ID: 35768709
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.
Miners AH; Sabin CA; Tolley KH; Lee CA
Pharmacoeconomics; 2002; 20(11):759-74. PubMed ID: 12201795
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy in hemophilia A: a cost-effectiveness analysis.
Machin N; Ragni MV; Smith KJ
Blood Adv; 2018 Jul; 2(14):1792-1798. PubMed ID: 30042145
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India.
Seth T; John MJ; Chakrabarti P; Shanmukhaiah C; Verma SP; Radhakrishnan N; Dolai TK
Haemophilia; 2024 Mar; 30(2):426-436. PubMed ID: 38147060
[TBL] [Abstract][Full Text] [Related]
17. Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.
Thorat T; Neumann PJ; Chambers JD
J Manag Care Spec Pharm; 2018 Jul; 24(7):632-642. PubMed ID: 29952709
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of an implantable cardioverterdefibrillator for the treatment of patients with ischemic or non-ischemic New York Heart Association class II or III heart failure in Colombia.
Atehortúa S; Senior JM; Castro P; Ceballos M; Saldarriaga C; Giraldo N; Mora G
Biomedica; 2019 Sep; 39(3):502-512. PubMed ID: 31584764
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A.
Colombo GL; Di Matteo S; Mancuso ME; Santagostino E
Clinicoecon Outcomes Res; 2011; 3():55-61. PubMed ID: 21935333
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India.
Seth T; Garg K; Mandal PK; Datta A; Verma S; Hanagavadi S; Thota UR
Hematology; 2023 Dec; 28(1):2277497. PubMed ID: 37933875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
